A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors.
Latest Information Update: 29 Sep 2011
At a glance
- Drugs OSI 930 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2009 Planned end date changed from 1 Dec 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 17 Jul 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov.